Helius Medical Technologies - יחס שווי חברה להכנסות HSDT

Helius Medical generates revenue from neurotechnology by implementing PoNS systems to restore motor function in multiple sclerosis patients. The EV/Sales ratio reflects the business valuation trend, with the current level standing at 7508.49. Financial stability is increasing alongside the medical adoption of these devices, while the automation of clinical trial data processing via software robots is accelerating the release of new products.
HSDT (heliusmedical.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Helius Medical investments in the development of the PoNS AI platform determine the long-term revenue growth potential within the neuromodulation niche. The EV/Sales history demonstrates the business value excluding debt per unit of revenue, allowing for an assessment of the extent to which market expectations for innovation outpace current financial results and where objective value is replaced by speculative investor belief.